Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Genes and Pathways Promoting Long‐Term Liver Repopulation by Ex Vivo hYAP‐ERT2 Transduced Hepatocytes and Treatment of Jaundice in Gunn Rats

Esther A. Peterson, Zsuzsanna Polgar, Gnanapackiam S. Devakanmalai, Yanfeng Li, Fadi L. Jaber, Wei Zhang, Xia Wang, Niloy J. Iqbal, John W. Murray, Namita Roy‐Chowdhury, Wilber Quispe‐Tintaya, Alexander Y. Maslov, Tatyana L. Tchaikovskaya, Yogeshwar Sharma, Leslie E. Rogler, Sanjeev Gupta, Liang Zhu, Jayanta Roy‐Chowdhury, David A. Shafritz – 20 November 2018 – Hepatocyte transplantation is an attractive alternative to liver transplantation. Thus far, however, extensive liver repopulation by adult hepatocytes has required ongoing genetic, physical, or chemical injury to host liver.

Con: The Unclear Benefit of Albumin

Alastair O’Brien – 17 November 2018 – Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.

Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Anna Suk‐Fong Lok – 15 November 2018 – Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

Maria G. Cardona‐Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley – 14 November 2018 – There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.

Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double‐Blind, Randomized Trial

Débora Raquel Benedita Terrabuio, Marcio Augusto Diniz, Lydia Teofilo de Moraes Falcão, Ana Luiza Vilar Guedes, Larissa Akeme Nakano, Andréia Silva Evangelista, Fabiana Roberto Lima, Clarice Pires Abrantes‐Lemos, Flair José Carrilho, Eduardo Luiz Rachid Cancado – 14 November 2018 – Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long‐term immunosuppression is associated with increased risk of neoplasias and infections.

LiverLearning®: 2018 Hepatitis Debrief

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Jorge A. Bezerra (Moderator) Jordan J. Feld Jordan J. Feld, MD, MPH, FAASLD attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis.

Subscribe to